PD-L1 / TCR Activator - CHO Recombinant Cell Line from BPS Bioscience, Inc.

Product Specs
ItemPD-L1 / TCR Activator - CHO Recombinant Cell Line
CompanyBPS Bioscience, Inc.
Price $11,945.00Supplier Page View Company Product Page
Catalog Number60536
Quantity2 vials
ApplicationsScreen for activators or inhibitors of PD-1 signaling in a cellular context, screen PD-L1 antibodies for binding affinity, Characterize the biological activity of PD-1 interactions with PD-L1
TypeCell Line
Cell LineCHO
Source/Expression Systemhamster
CHO
FormatAqueous solution containing DMSO

Add to Compare List

BPS Bioscience, Inc.

6405 Mira Mesa Blvd

Suite 100

San Diego, CA 92121

United States

Phone: 858-202-1401

Email: sales-team@bpsbioscience.com

Company Profile

Website: https://bpsbioscience.com/

(1) Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancerOncogenesisMarch 18, 2026Jung Ho Han, Eun-Ji Lee, Young-Hoon Park, Jung-Hye Ha, Kazi Rejvee Ahmed, Jang-Gi Choi, Hwan-Suck ChungCHO-K1 cells expressing human PD-L1 and a T-cell receptor (TCR) activator (hPD-L1/TCR CHO-K1 cells, #60536) were obtained from BPS Bioscience. Jurkat and CHO-K1 cells were infected with human PD-1- and PD-L1-expressing

(2) Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1mAbsDecember 31, 2025Keyla María Gómez Castellano, Alejandra Montes Luna, Gregorio de Jesús Carballo Uicab, Frida Daniela Ramírez Villedas, Luis Javier Elizarrarás Rodríguez, Said Kayum Vázquez Leyva, Stefany Daniela Rodríguez Luna, Edith González González, María Martha Pedraza Escalona, Ben Holland, et al.constitutively expressing hPD-L1 (PD-L1/TCR Activator CHO Recombinant cell line, BPS Bioscience Cat. No. 60536) (3.5x104 cells/well) were cultivated on Thaw Medium 3A (BPS Bioscience Cat. No. 60186) overnight at

(3) Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studiesmAbsDecember 31, 2024Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, et al.PD-L1/T cell receptor (TCR) activator- engineered CHO-K1 (commercial cell line, BPS Bioscience Inc., #60536), were plated in a 96-well plate at a density of 10,000 cells per well and incubated for 5 hours to

(4) An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicityCellular & molecular biology lettersMay 31, 2023Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, Zhu Z, Niu L, Zeng X, Zhang D, et al.Cell culture Recombinant PD-1/NFAT reporter Jurkat cells (no. 79687) and TCR-activator PD-L1/CHO cells (no. 60536) were purchased from BPS Bioscience (San Diego, USA), and FcγRIIIa (158 V) Jurkat effector cells (GM-C05619)

(5) Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse ModelFrontiers in immunologyJanuary 1, 2021Lee EJ, Kim JH, Kim TI, Kim YJ, Pak ME, Jeon CH, Park YJ, Li W, Kim YS, Choi JG, et al.T cells) and recombinant CHO-K1 cells expressing human PD-L1 and T cell receptor (TCR) activator (#60536, hPD-L1/TCR CHO-K1 cells) were purchased from BPS Bioscience. The hPD-1/NFAT Jurkat T cells were maintained

(6) Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockadeOncoimmunologyJanuary 1, 2021Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, Hess C, Tietz J, Johansson M, Spiga FM, et al.NFAT reporter gene assay CHO cells stably expressing PD-L1 and a TCR activator (BPS Bioscience, cat. 60536) were incubated with Jurkat T cells stably expressing PD-1 and a reporter gene to monitor T cell activation

Be the First to Write a Review!